These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15630492)

  • 1. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
    Lindhoff-Last E; Kreutzenbeck HJ; Magnani HN
    Thromb Haemost; 2005 Jan; 93(1):63-9. PubMed ID: 15630492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases].
    Schindewolf M; Magnani HN; Lindhoff-Last E
    Hamostaseologie; 2007 May; 27(2):89-97. PubMed ID: 17479171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran).
    Magnani HN
    Thromb Res; 2010 Apr; 125(4):297-302. PubMed ID: 19656552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
    Magnani HN; Gallus A
    Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation.
    Lindhoff-Last E; Bauersachs R
    Semin Thromb Hemost; 2002 Oct; 28(5):439-46. PubMed ID: 12420239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
    Kodityal S; Manhas AH; Udden M; Rice L
    Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T; Perry CM
    Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy.
    Gill J; Kovacs MJ
    Obstet Gynecol; 1997 Oct; 90(4 Pt 2):648-50. PubMed ID: 11770579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful use of a heparinoid (danaparoid sodium) for heparin-induced thrombocytopenia type II in aortic valve reoperation].
    Scheffler E; Aulmann M; Remppis A; Ziegler R; Martin E; Fleischer F; Nawroth P
    Z Kardiol; 1995 Jul; 84(7):565-8. PubMed ID: 7676727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Danaparoid sodium.
    Acostamadiedo JM; Iyer UG; Owen J
    Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
    Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
    Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Danaparoid in the prevention of thromboembolic complications.
    Skoutakis VA
    Ann Pharmacother; 1997; 31(7-8):876-87. PubMed ID: 9220051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
    Lubenow N; Warkentin TE; Greinacher A; Wessel A; Sloane DA; Krahn EL; Magnani HN
    Thromb Res; 2006; 117(5):507-15. PubMed ID: 15907979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure.
    Westphal K; Martens S; Strouhal U; Matheis G; Lindhoff-Last E; Wimmer-Greinecker G; Lischke V
    Thorac Cardiovasc Surg; 1997 Dec; 45(6):318-20. PubMed ID: 9477469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases.
    Tardy-Poncet B; Wolf M; Lasne D; Bauters A; Ffrench P; Elalamy I; Tardy B
    Intensive Care Med; 2009 Aug; 35(8):1449-53. PubMed ID: 19350215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative anticoagulation with danaparoid in two pregnancies in a patient with former heparin-induced thrombocytopenia (HIT), homozygous factor V Leiden mutation, a history of venous thrombosis and recurrent pregnancy losses.
    Schindewolf M; Lindhoff-Last E
    Thromb Haemost; 2008 Apr; 99(4):776-8. PubMed ID: 18392337
    [No Abstract]   [Full Text] [Related]  

  • 18. [Multidisciplinary consultation for the prescription of danaparoid in suspected heparin-induced thrombocytopenia].
    Verdy E; Debrix I; Benomar A; Becker A; Flahault A
    Presse Med; 2007 May; 36(5 Pt 1):786-93. PubMed ID: 17303370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative review of the adverse effect profiles of heparins and heparinoids.
    Borris LC; Lassen MR
    Drug Saf; 1995 Jan; 12(1):26-31. PubMed ID: 7537967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
    Ranze O; Ranze P; Magnani HN; Greinacher A
    Eur J Pediatr; 1999 Dec; 158 Suppl 3():S130-3. PubMed ID: 10650852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.